HT-4253

· Halia Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HT-4253, covering 2025-06-11 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers [Phase 2]